carbapenems has been researched along with tomopenem in 16 studies
| Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (tomopenem) | Trials (tomopenem) | Recent Studies (post-2010) (tomopenem) |
|---|---|---|---|---|---|
| 7,355 | 147 | 5,277 | 19 | 2 | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (81.25) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moland, ES; Thomson, KS | 1 |
| Abe, T; Fukuoka, T; Hirota, T; Inoue, H; Kakuta, M; Kitayama, A; Koga, T; Kuwahara, S; Masuda, N; Matsushita, Y; Nakagawa, M; Ohya, S; Shibayama, T; Sugihara, C; Takenouchi, T; Utsui, Y; Yoshida, T | 1 |
| Hirota, T; Ikeda, T; Kuwahara, S; Matsushita, Y; Shibayama, T | 1 |
| Hirota, T; Ikeda, T; Kawai, K; Kuwahara, S; Matsushita, Y; Shibayama, T | 1 |
| Hirota, T; Ikeda, T; Matsushita, Y; Shibayama, T; Tokui, T; Yamamura, N | 1 |
| Hirota, T; Ikeda, T; Kurihara, A; Matsushita, Y; Shibayama, T | 1 |
| Hirota, T; Ikeda, T; Kamiyama, E; Shibayama, T; Sugiyama, D; Tokui, T | 1 |
| Bowker, KE; MacGowan, AP; Noel, AR | 1 |
| Davies, BE; Kirkpatrick, C; Lennon, S; Liu, M; Luedin, E; Mallalieu, NL; Robson, R | 1 |
| Fukuoka, T; Kakuta, M; Koga, T; Masuda, N; Namba, E; Sugihara, C | 2 |
| Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Morinaga, Y; Nakamura, S; Seki, M; Yamada, Y; Yamamoto, K; Yamamoto, Y; Yanagihara, K | 1 |
| Davies, BE; Guy, T; Lennon, S; Liu, M; Luedin, E; Mallalieu, NL | 1 |
| Kakuta, M; Koga, T; Sugihara, C; Sugihara, K; Tomozawa, T | 1 |
| Inoue, H; Kakuta, M; Koga, T; Matsushita, Y; Namba, E; Nasu, H; Sugihara, C; Sugihara, K; Tokumitsu, A; Uemori, M; Yamamura, N | 1 |
| Koga, T; Sugihara, C; Sugihara, K; Tateda, K; Yamaguchi, K; Yamamura, N | 1 |
2 trial(s) available for carbapenems and tomopenem
| Article | Year |
|---|---|
Effect of impaired renal function on the pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
Topics: Adult; Aged; Bacterial Infections; Carbapenems; Creatinine; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Renal Insufficiency | 2008 |
Lack of age and gender effects on single-dose pharmacokinetics of tomopenem (RO4908463/CS-023), a novel carbapenem.
Topics: Adult; Age Factors; Aged; Area Under Curve; Carbapenems; Double-Blind Method; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Middle Aged; Sex Factors; Treatment Outcome; Young Adult | 2009 |
14 other study(ies) available for carbapenems and tomopenem
| Article | Year |
|---|---|
CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Bacterial Infections; Carbapenems; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Oxacillin; Penicillin Resistance; Penicillins; Pseudomonas aeruginosa; Staphylococcus; United States | 2004 |
In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Disease Models, Animal; Drug Resistance, Bacterial; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Mice; Microbial Sensitivity Tests | 2005 |
Pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem, in healthy male Caucasian volunteers.
Topics: Area Under Curve; Carbapenems; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Half-Life; Humans; Infusions, Parenteral; Male; Molecular Structure; White People | 2006 |
Pharmacokinetics and disposition of CS-023 (RO4908463), a novel parenteral carbapenem, in animals.
Topics: Animals; Carbapenems; Chromatography, Thin Layer; Dogs; Dose-Response Relationship, Drug; Feces; Haplorhini; Male; Molecular Structure; Radioisotopes; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2007 |
Renal handling of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in rabbits in comparison with meropenem.
Topics: Animals; Carbapenems; In Vitro Techniques; Kidney; Kidney Cortex; Kidney Tubules; Male; Meropenem; Metabolic Clearance Rate; Microsomes; Models, Animal; Rabbits; Thienamycins | 2006 |
Prediction of pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in humans using animal data.
Topics: Animals; Body Weight; Carbapenems; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate | 2007 |
Characterization of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters.
Topics: Algorithms; Anti-Bacterial Agents; Biological Transport, Active; Carbapenems; Carrier Proteins; Cationic Amino Acid Transporter 2; Cell Line; Humans; Kidney; Kinetics; Meropenem; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Organic Cation Transporter 1; Thienamycins | 2007 |
Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection.
Topics: Anti-Bacterial Agents; Carbapenems; Colony Count, Microbial; Drug Resistance, Bacterial; Humans; Methicillin; Methicillin Resistance; Microbial Sensitivity Tests; Staphylococcus aureus; Vancomycin | 2008 |
Potent in vitro activity of tomopenem (CS-023) against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: Carbapenems; Imipenem; Meropenem; Methicillin Resistance; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus; Thienamycins | 2008 |
In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Colony Count, Microbial; Humans; Lung; Male; Meropenem; Mice; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Serum; Thienamycins | 2008 |
Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
Topics: Carbapenems; Escherichia coli; Microbial Sensitivity Tests; Mutation; Penicillin-Binding Proteins; Pseudomonas aeruginosa; Staphylococcus aureus | 2009 |
In vitro postantibiotic effects of tomopenem (CS-023) against Staphylococcus aureus and Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Carbapenems; Drug Resistance, Bacterial; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus | 2010 |
In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Male; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred ICR; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Thigh | 2010 |
Efficacy of human-simulated exposures of tomopenem (formerly CS-023) in a murine model of Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus infection.
Topics: Animals; Carbapenems; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred ICR; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections | 2011 |